Related Experiment Videos
Proteomics for cancer biomarker discovery
Pothur R Srinivas1, Mukesh Verma, Yinming Zhao
1Division of Cancer Prevention, National Cancer Institute, Rockville, MD 20852, USA.
Clinical Chemistry
|July 27, 2002
Summary
Novel technologies enable comprehensive genomic, transcriptomic, and proteomic analyses for cancer research. Proteomics offers promise for biomarker discovery, impacting patient care and molecular diagnostics.
Area of Science:
- Genomics
- Transcriptomics
- Proteomics
- Molecular Medicine
- Cancer Research
Background:
- Emerging technologies facilitate comprehensive analyses of genomes, transcriptomes, and proteomes.
- These analyses are poised to accelerate cancer research and patient care.
- Molecular medicine can distinguish disease subtypes and identify genetic events in cancer progression.
Purpose of the Study:
- To review advances in proteomics for cancer biomarker discovery.
- To address challenges in sample preparation and specificity.
- To highlight efforts in biomarker discovery for clinical translation.
Main Methods:
- Review of current literature on proteomics in cancer research.
- Discussion of technological advancements in proteomic analysis.
- Examination of challenges in biomarker validation and clinical application.
Main Results:
- Proteomics shows significant promise for identifying novel cancer biomarkers.
- Distinguishing disease subtypes and identifying genetic events are key applications.
- Overcoming challenges in sample preparation and specificity is crucial for reliable biomarker discovery.
Conclusions:
- Proteomics is a powerful tool for cancer biomarker discovery.
- Further research is needed to address current challenges and facilitate clinical translation.
- Collaborative efforts, like those of the Early Detection Research Network, are vital for advancing biomarker discovery.